NCI Investigational Drugs, Pharmaceutical DataU. S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Cancer Institute, 1986 - Drugs Provides product information on investigational drug products sponsored by the Division of Cancer Treatment for clinical trials. |
Other editions - View all
Common terms and phrases
acid Aclarubicin Amonafide Amsacrine antibacterial preservatives Azacitidine Cancer Treatment CAUTION chemically stable clinical trials sponsored concentration contain 50 mg contains no antibacterial days at room Dextrose in 0.9 Dextrose Injection discarded 8 hours Division of Cancer dosage form contains drug exhibiting no decomposition Further dilution hours after initial hours at room hydroxide to adjust Ifosfamide infusion solutions initial entry intact ampules intact vials least 24 hours Leucovorin lyophilized dosage form Melphalan Menogaril Mercaptopurine mg of mannitol mg/ml Mitoguazone ml of Sterile ml will contain Molecular Formula N,N-Dimethylacetamide National Cancer Institute powder in 20 product be discarded product described product is prepared recommended results reconstituted as directed reconstituted product reconstituted solution Reconstitution as recommended refrigeration 2-8C refrigeration temperature 2-8C room temperature 22-25C Route of Administration single-use lyophilized dosage Sodium Chloride Injection sodium hydroxide Solution Preparation Sterile Water Storage stored at room stored under refrigeration vials are stable Water for Injection